<DOC>
	<DOCNO>NCT01178073</DOCNO>
	<brief_summary>The purpose study compare two treatment strategy ; first-line combination therapy ( ambrisentan tadalafil ) versus first-line monotherapy ( ambrisentan tadalafil ) subject Pulmonary Arterial Hypertension . This assessed time first clinical failure event .</brief_summary>
	<brief_title>A Study First-Line Ambrisentan Tadalafil Combination Therapy Subjects With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Subjects must diagnosis Pulmonary Arterial Hypertension ( PAH ) due following : a. idiopathic heritable PAH b. PAH associate : i. connective tissue disease ( e.g. , limited scleroderma , diffuse scleroderma , mixed connective tissue disease , systemic lupus erythematosus , overlap syndrome ) ii . drug toxins iii . Human Immunodeficiency Virus ( HIV ) infection iv . congenital heart defect repair great 1 year prior screening ( i.e. , atrial septal defect , ventricular septal defect , patent ductus arteriosus ) NB : subject portopulmonary hypertension pulmonary venoocclusive disease NOT eligible study Subject must current diagnosis World Health Organisation ( WHO ) Functional Class II III . Subject must meet follow haemodynamic criterion mean right heart catheterization prior screening : i. mPAP ≥25 mmHg ii . PVR ≥ 300 dynes/sec/cm5 iii . PCWP LVEDP ≤12 mmHg PVR ≥300 &lt; 500 dyne/sec/cm5 , PCWP/LVEDP ≤ 15 mmHg PVR ≥500 dynes/sec/cm5 Subject must walk distance ≥125m ≤500m screen visit Subject receive previous PAH therapy ( phosphodiesterase type 5 inhibitor ( PDE5i ) , endothelin receptor antagonist ( ERA ) , chronic prostanoid* ) within 4 week prior screen visit ( *Chronic prostanoid use consider &gt; 7 day treatment ) Subject receive ERA treatment ( e.g. , bosentan sitaxentan ) PDE5i treatment ( e.g . Sildenafil ) time AND discontinue due tolerance issue associate liver function abnormality Subjects previously discontinue ambrisentan tadalafil either another clinical study commercial product ( Volibris/Letairis Adcirca ) safety tolerability reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Ambrisentan</keyword>
	<keyword>Sponsor Rest World : GSK</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>PAH</keyword>
	<keyword>Sponsor US : Gilead</keyword>
</DOC>